In Finland, a 35-year-old man named Mika accessed a prescription for Ozempic, a popular weight loss drug, during a brief chat appointment with his doctor that lasted just over five minutes. After receiving the prescription, he promptly purchased the medication from a pharmacy and administered it through subcutaneous injection. Mika chose to participate in this article under a pseudonym to protect his sensitive health information, although it has been confirmed that Yle MOT reviewed the communications between Mika and his physician.

Motivated by a desire to transform his life post-holidays, Mika reflects on his previous weight loss attempts, including an earlier experience where he lost 30 kilograms through a low-carb diet, only to regain the weight later. At a height of 185 cm and weighing 120 kilograms at the start of his course with Ozempic, he was drawn to this medication due to its reputation for efficacy and the ease of obtaining a prescription via chat. Mika describes himself as someone who desires immediate results, illustrating a growing trend in Finland towards the accessibility of medications like semaglutide.

The Finnish social insurance institution Kela recently reported an all-time high in the sales of semaglutide, indicating a significant uptick in its usage among the population. This reflects not only individual choices like Mika's but also broader societal trends regarding obesity and the search for quick solutions in weight management. The article raises important questions about the implications of fast-track prescription services and their impact on public health and medical practices.